Abstract
Introduction: Although histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better efficacy for pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and large cell carcinoma) carcinoma than in squamous cell carcinoma. Herein, retrospective analysis is used to explore the potential predictive and prognostic role of non-small cell lung cancer histology in patients treated with three first-line, platinum-based regimens. Methods: Survival and time to progression (TTP) data from a phase III trial comparing paclitaxel plus carboplatin (PCb), GC, and vinorelbine plus cisplatin (VC) were analyzed. Using Cox multiple regression, factors for one model included treatment (PCb, GC, and VC), histology (squamous, adenocarcinoma, large cell, and other), gender, Eastern Cooperative Oncology Group performance status (0/1 and 2), stage (IIIB and IV), number of metastatic sites (≤1 and >1), and smoking history (yes or no). In another model, histology was simply considered as squamous versus nonsquamous. An interaction value of p <0.10 was considered significant. Results: Baseline patient and disease characteristics for the 607 treated patients were balanced among the arms. No significant treatment-by-histology interaction was seen in either model for either end point. Nevertheless, histology was a significant prognostic factor for survival in the first model (p = 0.0183) and marginally significant for TTP (p = 0.0783). Subsequent pairwise comparisons of histology groups demonstrated a survival advantage for squamous cell carcinoma over adenocarcinoma (p = 0.0021). CONCLUSIONS:: Histology was not predictive of PCb, GC, or VC treatment effect for either survival or TTP. Histology was prognostic for survival, with better outcomes associated with squamous cell carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 1568-1571 |
| Number of pages | 4 |
| Journal | Journal of Thoracic Oncology |
| Volume | 4 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2009 |
Fingerprint
Keywords
- Histology
- Nonsmall cell lung cancer
- Predictive factor
- Prognostic factor
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
The role of histology with common first-line regimens for advanced non-small cell lung cancer : A brief report of the retrospective analysis of a three-arm randomized trial. / Scagliotti, Giorgio V.; De Marinis, Filippo; Rinaldi, Massimo; Crinò, Lucio; Gridelli, Cesare; Ricci, Sergio; Zhao, Yan D.; Liepa, Astra M.; Peterson, Patrick; Tonato, Maurizio.
In: Journal of Thoracic Oncology, Vol. 4, No. 12, 12.2009, p. 1568-1571.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of histology with common first-line regimens for advanced non-small cell lung cancer
T2 - A brief report of the retrospective analysis of a three-arm randomized trial
AU - Scagliotti, Giorgio V.
AU - De Marinis, Filippo
AU - Rinaldi, Massimo
AU - Crinò, Lucio
AU - Gridelli, Cesare
AU - Ricci, Sergio
AU - Zhao, Yan D.
AU - Liepa, Astra M.
AU - Peterson, Patrick
AU - Tonato, Maurizio
PY - 2009/12
Y1 - 2009/12
N2 - Introduction: Although histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better efficacy for pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and large cell carcinoma) carcinoma than in squamous cell carcinoma. Herein, retrospective analysis is used to explore the potential predictive and prognostic role of non-small cell lung cancer histology in patients treated with three first-line, platinum-based regimens. Methods: Survival and time to progression (TTP) data from a phase III trial comparing paclitaxel plus carboplatin (PCb), GC, and vinorelbine plus cisplatin (VC) were analyzed. Using Cox multiple regression, factors for one model included treatment (PCb, GC, and VC), histology (squamous, adenocarcinoma, large cell, and other), gender, Eastern Cooperative Oncology Group performance status (0/1 and 2), stage (IIIB and IV), number of metastatic sites (≤1 and >1), and smoking history (yes or no). In another model, histology was simply considered as squamous versus nonsquamous. An interaction value of p <0.10 was considered significant. Results: Baseline patient and disease characteristics for the 607 treated patients were balanced among the arms. No significant treatment-by-histology interaction was seen in either model for either end point. Nevertheless, histology was a significant prognostic factor for survival in the first model (p = 0.0183) and marginally significant for TTP (p = 0.0783). Subsequent pairwise comparisons of histology groups demonstrated a survival advantage for squamous cell carcinoma over adenocarcinoma (p = 0.0021). CONCLUSIONS:: Histology was not predictive of PCb, GC, or VC treatment effect for either survival or TTP. Histology was prognostic for survival, with better outcomes associated with squamous cell carcinoma.
AB - Introduction: Although histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better efficacy for pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and large cell carcinoma) carcinoma than in squamous cell carcinoma. Herein, retrospective analysis is used to explore the potential predictive and prognostic role of non-small cell lung cancer histology in patients treated with three first-line, platinum-based regimens. Methods: Survival and time to progression (TTP) data from a phase III trial comparing paclitaxel plus carboplatin (PCb), GC, and vinorelbine plus cisplatin (VC) were analyzed. Using Cox multiple regression, factors for one model included treatment (PCb, GC, and VC), histology (squamous, adenocarcinoma, large cell, and other), gender, Eastern Cooperative Oncology Group performance status (0/1 and 2), stage (IIIB and IV), number of metastatic sites (≤1 and >1), and smoking history (yes or no). In another model, histology was simply considered as squamous versus nonsquamous. An interaction value of p <0.10 was considered significant. Results: Baseline patient and disease characteristics for the 607 treated patients were balanced among the arms. No significant treatment-by-histology interaction was seen in either model for either end point. Nevertheless, histology was a significant prognostic factor for survival in the first model (p = 0.0183) and marginally significant for TTP (p = 0.0783). Subsequent pairwise comparisons of histology groups demonstrated a survival advantage for squamous cell carcinoma over adenocarcinoma (p = 0.0021). CONCLUSIONS:: Histology was not predictive of PCb, GC, or VC treatment effect for either survival or TTP. Histology was prognostic for survival, with better outcomes associated with squamous cell carcinoma.
KW - Histology
KW - Nonsmall cell lung cancer
KW - Predictive factor
KW - Prognostic factor
UR - http://www.scopus.com/inward/record.url?scp=74249111124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74249111124&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e3181c06980
DO - 10.1097/JTO.0b013e3181c06980
M3 - Article
C2 - 20009911
AN - SCOPUS:74249111124
VL - 4
SP - 1568
EP - 1571
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 12
ER -